Revenue
200 million USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 199878000 USD Source
Fundies. English
COLLEGIUM PHARMACEUTICAL, INC.
EDGARAnnual consolidated revenue for 2025: about USD 780.6M, using the latest reported figures. The previous period, 2024, was about USD 631.4M.
Latest quarter
Operating margin
1.85%
2026 Q2 · %
Operating cash flow
71.3 million USD
2026 Q2 · USD
Free cash flow
70.8 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 129 million USD Source
Exact value
129467000 USD
- Long-term debt including current maturities
- 11.5 million Unit_Standard_USD_o0dyjS3eHE62R4MLCZmlcw Source
Exact value
11500000 Unit_Standard_USD_o0dyjS3eHE62R4MLCZmlcw
- Shares outstanding
- 32.5 million shares Source
Exact value
32498310 shares
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-19.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 3 of 11 periods available· newest 2025-12-31
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2025-12-31
- Total assets: 2 of 11 periods available· newest 2025-12-31
- Total liabilities: 2 of 11 periods available· newest 2025-12-31
- Current assets: 2 of 11 periods available· newest 2025-12-31
- Current liabilities: 2 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2019-12-31
- Shares outstanding: 2 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+23.6%Prior period
USD 631.45 million
–
Current period
USD 780.57 million
–
Exact inputs and evidence
780567000 − 631449000 = 149118000 USD
631449000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source780567000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
-9.1%Prior period
USD 69.19 million
–
Current period
USD 62.87 million
–
Exact inputs and evidence
62870000 − 69190000 = -6320000 USD
69190000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source62870000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+60.7%Prior period
USD 204.98 million
–
Current period
USD 329.32 million
–
Exact inputs and evidence
329323000 − 204980000 = 124343000 USD
204980000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source329323000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+5.3%Prior period
USD 1.65 million
–
Current period
USD 1.74 million
–
Exact inputs and evidence
1740000 − 1652000 = 88000 USD
1652000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source1740000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 780.57 million 100% of revenue
- Cost of revenue USD 317.31 million 41% of revenue
- Operating expenses USD 283.62 million 36% of revenue
- Operating income USD 179.64 million 23% of revenue
- Tax, interest and other Derived USD 116.77 million 15% of revenue
- Net income USD 62.87 million 8.1% of revenue
Cash
- Operating cash flow USD 329.32 million 42% of revenue
- Capital expenditure USD 1.74 million 0.2% of revenue
- Free cash flow Derived USD 327.58 million 42% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2023 21%71%
- 2024 11%16%73%
- 2025 15%77%
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | 566767000 | 399806000 Derived | 166961000 | 118806000 Derived | 48155000 | 274288000 Derived | Source
|
| 2024 2024-01-01 – 2024-12-31 | 631449000 | 461554000 Derived | 169895000 | 100705000 Derived | 69190000 | 203328000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 780567000 | 600931000 Derived | 179636000 | 116766000 Derived | 62870000 | 327583000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 780.6M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Revenue | 566767000 |
|
| 2024 | Revenue | 631449000 |
|
| 2025 | Revenue | 780567000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
23.6% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Year over year | No prior comparable period |
|
| 2024 | Year over year | 11.4% |
|
| 2025 | Year over year | 23.6% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin 23% 2025
Net margin 8.1% 2025
Free cash flow margin 42% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Operating margin | 29.5% |
|
| 2024 | Operating margin | 26.9% |
|
| 2025 | Operating margin | 23% |
|
| 2023 | Net margin | 8.5% |
|
| 2024 | Net margin | 11% |
|
| 2025 | Net margin | 8.1% |
|
| 2023 | Free cash flow margin | 48.4% |
|
| 2024 | Free cash flow margin | 32.2% |
|
| 2025 | Free cash flow margin | 42% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD 329.3M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Operating cash flow | 274749000 |
|
| 2024 | Operating cash flow | 204980000 |
|
| 2025 | Operating cash flow | 329323000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD 327.6M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Free cash flow | 274288000 |
|
| 2024 | Free cash flow | 203328000 |
|
| 2025 | Free cash flow | 327583000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
81.8% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2024 | Liabilities / assets | 86.2% |
|
| 2025 | Liabilities / assets | 81.8% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
1.57× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2024 | Current assets / current liabilities | 0.95× |
|
| 2025 | Current assets / current liabilities | 1.57× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | USD 48.16 million Exact valueExact value: 48155000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 274.75 million Exact valueExact value: 274749000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 461,000 Exact valueExact value: 461000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 274.29 million Calculation and evidence274749000 − 461000 USD Exact free cash flow: 274288000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | USD 69.19 million Exact valueExact value: 69190000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 204.98 million Exact valueExact value: 204980000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.65 million Exact valueExact value: 1652000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 203.33 million Calculation and evidence204980000 − 1652000 USD Exact free cash flow: 203328000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | USD 62.87 million Exact valueExact value: 62870000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 329.32 million Exact valueExact value: 329323000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.74 million Exact valueExact value: 1740000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 327.58 million Calculation and evidence329323000 − 1740000 USD Exact free cash flow: 327583000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
58 filings · 7,046 latest values · 7,046 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001267565, 1267565, COLL, edgar:1267565
Also known as COLLEGIUM PHARMACEUTICAL INC, COLLEGIUM PHARMACEUTICAL, INC, COLLEGIUM PHARMACEUTICAL, INC., Collegium Pharmaceutical, Inc, Collegium Pharmaceutical, Inc., Collegium Pharmaceutical, Inc.